NYU LANGONE HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1841-01-01

Employees: 10K

Market Cap: -

Website: http://www.nyulangone.org

Clinical Trials

Optimal Location of Nerve Block to Minimize Perioperative Opioid Administration in ACL Surgery: Comparing True Adductor Canal to Proximal Block

Phase 4

Completed

Conditions: ACL Surgery

Interventions: Drug: ACB proximal to true AC with bupivacaine 0.5% 20cc
Drug: ACB within true AC with bupivacaine 0.5% 20cc

First Posted Date: 2018-01-17

Last Posted Date: 2023-07-14

Lead Sponsor: NYU Langone Health

Target Recruit Count: 69

Registration Number: NCT03401450

Locations: 🇺🇸
New York University School of Medicine, New York, New York, United States

Burnout and Approach to Bereavement Initiatives in a Medical Intensive Care Unit (ICU)

Not Applicable

Completed

Conditions: Burnout, Professional

Interventions: Diagnostic Test: Survey

First Posted Date: 2018-01-12

Last Posted Date: 2020-06-05

Lead Sponsor: NYU Langone Health

Target Recruit Count: 50

Registration Number: NCT03398460

Locations: 🇺🇸
New York University School of Medicine, New York, New York, United States

Incorporating Financial Incentives to Increase Smoking Cessation Among Asian Americans Residing in New York City

Not Applicable

Completed

Conditions: Smoking, Cigarette
Smoking Cessation

Interventions: Behavioral: Financial Incentives

First Posted Date: 2018-01-12

Last Posted Date: 2019-11-08

Lead Sponsor: NYU Langone Health

Target Recruit Count: 10

Registration Number: NCT03397511

Locations: 🇺🇸
New York University School of Medicine, New York, New York, United States

Developing Advanced Blood-Brain Barrier Permeability Imaging for Early AD

Completed

Conditions: Alzheimer Disease

Interventions: Device: GRASP Dynamic Contrast-Enhanced (DCE) MRI
Device: 3T Brain Scan
Drug: Gadolinium-based Contrast Agent (GBCA) for MRI

First Posted Date: 2018-01-03

Last Posted Date: 2024-01-30

Lead Sponsor: NYU Langone Health

Target Recruit Count: 27

Registration Number: NCT03389698

Locations: 🇺🇸
New York University School of Medicine, New York, New York, United States

Can PRP Reduce Pro-Inflammatory Biomarkers Following ACL Injury

Phase 2

Withdrawn

Conditions: ACL - Anterior Cruciate Ligament Rupture
ACL Injury

Interventions: Biological: Platelet Rich Plasma
Other: Saline Placebo

First Posted Date: 2018-01-03

Last Posted Date: 2024-04-15

Lead Sponsor: NYU Langone Health

Registration Number: NCT03389685

Locations: 🇺🇸
New York University School of Medicine, New York, New York, United States

Efficacy of a Gluten-free Diet in Difficult to Manage Nephrotic Syndrome: Utility of Plasma Zonulin Levels as a Predictive Biomarker

Completed

Conditions: Nephrotic Syndrome

Interventions: Other: Implementation of a gluten-free diet

First Posted Date: 2017-12-29

Last Posted Date: 2021-06-22

Lead Sponsor: NYU Langone Health

Target Recruit Count: 13

Registration Number: NCT03387176

Locations: 🇺🇸
New York University School of Medicine, New York, New York, United States

HCV Positive Heart Donors

Phase 4

Completed

Conditions: Heart Failure

Interventions: Combination Product: Transplant with HCV positive donor, followed by surveillance and treatment of viremia

First Posted Date: 2017-12-26

Last Posted Date: 2021-02-03

Lead Sponsor: NYU Langone Health

Target Recruit Count: 25

Registration Number: NCT03382847

Locations: 🇺🇸
NYU Langone Transplant Institute, New York, New York, United States

3D MR Versus 3D CT for Glenohumeral Arthritis

Not Applicable

Completed

Conditions: Arthritis
Glenohumeral Osteoarthritis

Interventions: Diagnostic Test: 3-dimensional (3D) magnetic resonance (MR) imaging
Diagnostic Test: 3D computed tomography (CT) imaging

First Posted Date: 2017-12-20

Last Posted Date: 2021-03-25

Lead Sponsor: NYU Langone Health

Target Recruit Count: 31

Registration Number: NCT03379545

Locations: 🇺🇸
New York University School of Medicine, New York, New York, United States

Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma

Phase 2

Completed

Conditions: MGMT-unmethylated Glioblastoma (GBM)
GBM

Interventions: Drug: Nivolumab
Drug: Ipilimumab
Radiation: Radiation Therapy (RT)

First Posted Date: 2017-12-11

Last Posted Date: 2022-07-01

Lead Sponsor: NYU Langone Health

Target Recruit Count: 10

Registration Number: NCT03367715

Locations: 🇺🇸
New York University School of Medicine, New York, New York, United States

Comparative Analysis of Transperineal Versus Transrectal Approaches for MRI-Targeted Biopsy of the Prostate for the Detection and Characterization of Prostate Cancer

Not Applicable

Terminated

Conditions: Prostate Cancer

Interventions: Device: Artemis™ software system

First Posted Date: 2017-12-08

Last Posted Date: 2022-03-23

Lead Sponsor: NYU Langone Health

Target Recruit Count: 46

Registration Number: NCT03366792

Locations: 🇺🇸
New York University School of Medicine, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy